Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANGEL-TNK
NCT05624190Phase 4Recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Feb 2023
- Primary completion
- Jul 2024
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tenecteplase in ischemic stroke (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Rate of excellent outcome at 90 days. Started Feb 2023; status: recruiting.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05624190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05624190.